On May 18 , 2022 Allarity Therapeutics, Inc. (NASDAQ: ALLR) reported that its press release issued under the headline "Allarity Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update" on May 16, 2022, included a typographical error in the section titled "Full Year 2021 and Recent Highlights", describing the size of the debt cancellation which should have read "$971 thousand" instead of "$971 million (Press release, Allarity Therapeutics, MAY 18, 2022, View Source [SID1234614870])." The corrected paragraph is set forth below:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Full Year 2021 and Recent Highlights

In March 2022, entered into two agreements amending the LiPlaCis program. As a result of this amendment, Allarity will be exempt from any future financial obligation associated with the further development of LiPlaCis, including the cancellation of outstanding liability of $971 thousand. Allarity will also maintain its ability to receive possible future milestone payments of up to $3.5 million